CATALYST PHARMACEUTICALS INC
Catalyst Pharmaceuticals (CPRX) is a US-based specialty biopharmaceutical company focused on therapies for rare neuromuscular and other orphan diseases. Its revenue to date has largely been driven by sales of its lead product for a specific neuromuscular disorder, with future growth depending on label expansions, new approvals and international launches. Investors should note the typical small-cap biotech profile: potential for step‑change upside from regulatory successes, balanced by execution, regulatory, patent and market-concentration risks. Financials can be variable and the share price may react strongly to clinical, commercial or legal news. This summary is for general educational purposes only and not personal investment advice. Consider your risk tolerance, time horizon and seek independent financial or tax advice before acting. Past performance is not a guide to the future and returns are not guaranteed.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Catalyst Pharmaceuticals' stock due to its promising future value.
Financial Health
Catalyst Pharmaceuticals is performing well with strong profits and cash flow, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Baskets Featuring CPRX
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue Concentration
Sales are currently driven by a small number of products; this can mean rapid upside from launches but also high sensitivity to setbacks.
Regulatory Catalysts
Approvals, label expansions or international launches can materially affect valuation, though outcomes are uncertain and timing can vary.
Orphan Market Dynamics
Targeting rare diseases can offer premium pricing and patient loyalty, yet commercial scale is limited and healthcare policy changes can impact access.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
